2nd dose FLUZONE HD was admisntered instead of Prevnar 20 with no reported adverse event; 2nd dose FLUZONE HD was admisntered instead of Prevnar 20 with no reported adverse event; Initial information received on 24-Jan-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 90 years old male patient who received 2nd dose INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HD] was admisntered instead of PNEUMOCOCCAL VACCINE CONJ 20V (CRM197) (PREVNAR 20) with no reported adverse event. The patient’s past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 18-Oct-2024, the patient received 0.5 ml of 1 and dose 2 (on 22-Jan-2025) of suspect, INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE, Suspension for injection in pre-filled syringe (lot UT8470CA and expiry 30-JUN-2025) via intramuscular route in the left deltoid for Influenza instead of prevnar 20 with no reported adverse event (wrong product administered) (extra dose administered) (latency same day). Reportedly: Once they realized their mistake, they went ahead and gave the patient Prevnar 20. Medical assistant is asking if there would be safety concerns with regards to the situation. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder’s compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.